Please login to Zacks.com or register to post a comment.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| NATUS MEDICA | BABY | 6.11% |
| SUMMER INFAN | SUMR | 6.02% |
| RADIANT LOGI | RLGT | 5.32% |
| NEW ORIENTAL | EDU | 4.51% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Synovus Financial Corp. ( SNV - Analyst Report ) reported first-quarter 2011 loss attributable to common shareholders of 12 cents per share, a significant improvement from the loss of 47 cents per share reported in the year-ago quarter and 23 cents in the prior quarter. Moreover, the quarter’s earnings were in line with the Zacks Consensus Estimate.
Excluding $24.3 million of restructuring charges, the net loss attributable to common shareholders was $69.3 million or 9 cents per common share.
Net loss decreased to $93.7 million from $229.8 million in the prior-year quarter and $180.0 million in the prior quarter. The recovery was possible due to improved credit trends with a significant decline in credit costs and stable core performance.
Quarter in Detail
In the first quarter of 2011, net interest income decreased 4.6% to $237.4 million from $248.9 million in the year-ago period and also declined 2.0% from $242.0 million in the prior quarter, due to lower loan balances. Net interest margin was 3.52%, up from 3.37% in the prior quarter driven by a decrease in the effective cost of funds, a lower negative impact of non-performing assets and a drop in excess liquidity. The margin also exceeded 3.39% reported in the prior-year quarter.
Synovus’ interest expenses also decreased 14.8% sequentially and 35.1% year over year to $61.0 million in the reported quarter.
Non-interest income plummeted 7.9% to $64.2 million in the quarter from $69.7 million in the year-ago period. The decline was attributable to a fall in fee income, lower service charges on deposit accounts and decreased mortgage banking income, partially offset by an upswing in bankcard income brokerage, fiduciary and asset management fees and other non-interest income.
Non-interest income also edged down 19.6% sequentially, mainly due to lowered NSF fees, decreased mortgage and brokerage revenues.
Total revenue decreased 5.3% to $301.6 million from $318.6 million in the year-ago period and 6.3% sequentially from $321.9 million in the prior quarter. The decline was attributable to lower net-interest income and non-interest income. Moreover, revenue also lagged the Zacks Consensus Estimate of $313.0 million.
In the first quarter of 2011, total non-interest expenses decreased 5.2% year over year to $239.7 million. The decline was mainly due to lower foreclosed real estate expense and FDIC insurance and other regulatory fees, lower salaries and other personnel expense, professional fees, data processing expense, net occupancy and equipment expense, partially offset by higher other operating expenses.
Total credit costs dropped 37.2% to $177.0 million in the quarter from $282.0 million in the previous quarter.
Capital Position
As of March 31, 2011, Tier 1 capital ratio, Tier 1 common equity ratio and tangible common equity/ tangible assets ratio remained modestly in line at 12.8%, 8.5% and 6.7% compared with the prior-quarter ratios of 12.8%, 8.6% and 6.7%, respectively.
At the end of the reported quarter, total non-performing assets were down 0.4% sequentially and 30.8% year over year to $1.3 billion, impacted by lower inflows. However, net charge-offs decreased to $167 million in the quarter from $385 million in the prior quarter, the lowest level since the third quarter of 2008.
Total loans edged down $588 million during the quarter compared with a $995 million decline during the fourth quarter of 2010, and a $966 million decline in the prior-year quarter. The lower rate of decline during the quarter was driven by a decrease in loan dispositions and charge-offs.
Our Take
We believe Synovus is in a recovery phase, reflected by lower non-performingassets and improving operating efficiencies, which should make the company profitable in the upcoming quarters. Furthermore, the asset disposition activity will act as a positive catalyst for the company.
Synovus currently retains its Zacks #3 Rank, which translates to a short-term ‘Hold’ rating. However, Synovus’ closest competitor - Capital City Bank Group Inc. ( CCBG - Snapshot Report ) retains a Zacks #1 Rank (a short-term ‘Strong Buy’ rating).
Read the full Analyst Report on SNV
Read the full Snapshot Report on CCBG